TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03535259

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent sorafenib and IMRT, followed sorafenib maintenance
Description: IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
Study: NCT02941016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab or Alirocumab
Description: All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
Study: NCT03679533

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-Dried Cranberry Powder
Description: Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
Study: NCT02631525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous anesthesia based on propofol
Study: NCT03048903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheum Palmatum Root
Description: Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch Corn
Description: Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
Study: NCT02334449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LML134
Description: LML134 will be administered first as single doses and then as multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LML134
Description: LML134 will be administered first as single doses and then as multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All study cohorts (except food effect cohort) are placebo controlled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All study cohorts (except food effect cohort) are placebo controlled
Study: NCT00492167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-glucan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 3F8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT02810665

Intervention type: BEHAVIORAL
Intervention: Visual acuity measurement by ETDRS chart
Description: All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.

Intervention type: BEHAVIORAL
Intervention: Visual acuity measurement by ETDRS chart
Description: All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
Study: NCT02829138

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic information and Omega-3 fat intake
Description: Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Nutrition related to Omega-3 fats
Description: Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Nutrition related to Omega-3 fats
Description: Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
Study: NCT04510233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin nasal
Description: Ivermectin nasal spray one ml in each nostril two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin oral
Description: Ivermectin oral (one tablet 6 mg three times daily)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: oxygen via masks or ventilators
Study: NCT03383445

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Edwards
Description: The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CoreValve
Description: The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acurate neo
Description: The TAVR procedure will be performed with the ACURATE neo aortic valve.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard
Description: The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
Study: NCT00712699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: XR-MAS then placebo
Description: XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: XR-MAS then placebo
Description: XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 Placebo then XR-MAS
Description: PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 Placebo then XR-MAS
Description: PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Study: NCT00577785

Intervention type: OTHER
Intervention: tissue procurement
Description: No intervention. Tissue procurement study.
Study: NCT04243590

Intervention type: BEHAVIORAL
Intervention: Hand-Use-at-Home Questionnaire (HUH)
Description: The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).

Intervention type: BEHAVIORAL
Intervention: Hand-Use-at-Home Questionnaire (HUH)
Description: The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).

Intervention type: BEHAVIORAL
Intervention: Pediatric Outcome Data Collection Instrument (PODCI)
Description: The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).

Intervention type: BEHAVIORAL
Intervention: Children's Hand-Use Experience Questionnaire (CHEQ)
Description: The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children \<six years in this study.
Study: NCT04819152

Intervention type: BEHAVIORAL
Intervention: Tobacco cessation intervention
Description: Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden

Intervention type: BEHAVIORAL
Intervention: Tobacco cessation intervention
Description: Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
Study: NCT03666455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
Study: NCT02411539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
Study: NCT04715061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting state (Control)
Description: Participants were asking to sit on a sofa for 50 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting state (Control)
Description: Participants were asking to sit on a sofa for 50 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting state (Control)
Description: Participants were asking to sit on a sofa for 50 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Description: MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Description: MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Description: HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HIIE)
Description: HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Exercise (HIIE)
Description: HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
Study: NCT01002235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Intramuscular injections in the calf on Day 0 and Day 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Intramuscular injections in the calf on Day 0 and Day 14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Intramuscular injections in the calf on Day 0 and Day 14.
Study: NCT03016325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study: NCT01956903

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogenic Mesenchymal Stem Cell
Description: Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)
Study: NCT03961815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Induction Dose
Description: Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Maintenance Dose
Description: Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
Study: NCT02231164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: intravenous chemotherapy drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: intravenous chemotherapy drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: oral experimental therapy
Study: NCT04241211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forsteo
Description: Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Prefilled Syringe [Prolia]
Description: Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
Study: NCT01774578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Lung Immunotherapy
Description: HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute®-Lung Immunotherapy
Description: HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Study: NCT03983577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of service delivery model
Description: Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
Study: NCT04075838

Intervention type: OTHER
Group type: OTHER
Intervention: Recovery group
Description: The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
Study: NCT00823498

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: 6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview with a member of study staff at housing development site.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview with a member of study staff at housing development site.

Intervention type: OTHER
Intervention: Photovoice Project
Description: Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).

Intervention type: OTHER
Intervention: Photovoice Project
Description: Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
Study: NCT03009032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PMT25341

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose
Study: NCT02012985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxabact OC5 capsules
Description: The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
Study: NCT00606320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg(4 tablets)/day